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Correspondence
our experimentation could eventually be used
to discredit our findings, should they happen
not to agree with the original observations.
It seems important that all experiments in
the rapidly expanding area of endocrine dis-
ruption toxicology should be carefully
designed and fully reported. The use ofcon-
current positive and negative control groups
also seems to be prudent. These needs are
independent of who conducts or sponsors
studies. Good science is good science. Finally,
it should be noted that the onlyformal retrac-
tion ofendocrine disruption data currently
encountered derived from an academic labo-
ratory (15), a salutary counterbalance to the
assertions that stimulated this letter (1-3).
JohnAshby
Jenny Odum
Zeneca Central Toxicology Laboratory
Alderley Park, Cheshire, United Kingdom
REFERENCES AND NOTES
1. Anonymous. Industry and scientists in cross-fire on
endocrine-disrupting chemicals. ENDS Reports
268:26-29(1997).
2. Anonymous. Controversy over bisphenol A research.
Endocrine/Estrogen Newsletter3(12):1-4 (1997).
3. Anonymous. Industry funding provokes controversy.
Endocrine/EstrogenLetter4(4):5-6(1998).
4. Ashby J, Elliott HM. Reproducibility of endocrine dis-
ruption data. RegulToxicol Pharmacol 26:94-95 (1997).
5. Colerangle JB, Roy D. Perturbaton of cell cycle kinet-
ics in the mammary gland by stilbene estrogen,
diethylstilbestrol (DES). CancerLett94:55-63(1995).
6. Colerangle JB, Roy D. Exposure of environmental
estrogenic compound nonylphenol to Noble rats alters
cell-cycle kinetics in the mammary gland. Endocrine
4:115-122(1996).
7. Colerangle JB, Roy D. Profound effects of the weak
environmental estrogen-like chemical bisphenol A on
the growth of the mammary gland of Noble rats. J
Steroid Biochem Mol Biol60:153-160(1997).
8. Lee PC, Lee W. In vivo estrogenic acton of nonylphe-
nol in immature female rats. Bull Environ Contam
Toxicol57:341-348(1996).
9. Odum J, Lefevre PA, Tittensor S, Paton D, Routledge
EJ, Beresford NA, Sumpter JP, Ashby J. The rodent
uterotrophic assay: critical protocol features, studies
with nonylphenols, comparison with a yeast estro-
genicity assay. Regul Toxicol Pharmacol 25:176-188
(1997).
10. Ashby J, Tinwell H. Uterotrophic activity of bisphenol-
Atothe immature rat.(Submitted).
11. Dodds EC, Lawson W. Synthetic oestrogenic agents
without the phenanthrene nucleus. Nature 137:996
(1936).
12. Foley J, Ton T, Marenpot R. Butterworth B,
Goldsworthy TI. Comparison of proliferating cell
nuclear antigen to tritiated thymidine as a marker of
proliferating hepatocytes in rats. Environ Health
Perspect101(suppl 5):199-206(1993).
13. Nagel SC,vomSaal FS,ThayerKA,DharMG,Boechler
M,Welshons WV.Relatve binding affinity-serum mod-
ified access (RBA-SMA) assay predicts the relative in
vivo bioactivity ofthe xenoestrogens bisphenol A and
octylphenol. Environ Health Perspect105:70-76(1997).
14. vom Saal FS, Timms BG, Montano MM, Palanza P,
Thayer KA, Nagel SC, Dhar MD, Gunjam VK,
Parmigiani S, Welshons WV. Prostate enlargement in
mice duetofetal exposure to lowdoses ofestradiol or
diethylstilbestrol and opposite effects athigh dose lev-
els. Proc NatlAcad Sci USA94:2056-2061 (1997).
15. McLachlan JA. Synergistic effect of environmental
estrogens: report withdrawn. Science 277:462-463
(1997).
Response
In a paper we published last year (1), we
described biological effects in vivo on the
rodent prostate caused by fetal exposure to
very low doses of the environmental estrogen
bisphenol A; this low-dose effect was predicted
by a new in vitro assay. For the in vivo end
point of prostate enlargement, the effect pro-
duced by bisphenol A mimicked the effect of
fetal exposure to low doses ofthe natural and
synthetic estrogens estradiol and DES, which
were reported in another paper (2). Fetuses
were exposed to bisphenol A by feeding preg-
nant female mice at average maternal doses of
2 and 20 sg/kg maternal bodyweight per day
(2 and 20 ppb); these exposure levels produced
enlarged prostates measured in subsequent
adulthood. Our conclusion was that these
doses of bisphenol A, up to 25,000 times
lower than the previously reported NOAEL
(no observed adverse effect level) for bisphenol
A (3), were near andwithin reported ranges of
current human exposures from different
sources of this chemical (4,5). Three subse-
quent reports by two other groups have con-
firmed our finding ofhigh estrogenic bioactiv-
ity of bisphenol A in vivo using end points
(pituitary and mammary gland responses) that
were different from ours (6-il.
We find perplexing the statement ofAshby
and Odum that "many new findings in this
area are either inadequately described or are
based on inadequate test protocols. This makes
it difficult to conduct faithful repeat experi-
ments." The information that went into our
experimental design is based on more than 50
years of combined experience in hormone
action and control ofdevelopment. It is impos-
sible to put all ofthis information in any one
paper, and experimental details that have been
published previously are typically not repeated
[for example, see (9,10)]. For these reasons,
when we are interested in replicating an experi-
ment, we contact the original authors, and
other scientists have often contacted us for the
same reason. Forexample, Ashbyhas contacted
us on numerous occasions concernig experi-
mental procedures for the replication of our
studies. In addition, we recendy ran a training
session forlaboratorypersonnel from a contract
laboratory hired by the Society of the Plastics
Industry to replicate our study with bisphenol
A. Given this degree ofcooperation withAshby
and others associated with the chemical indus-
try, which is also true for Richard Sharpe (11),
we are puzzled as to why Ashby and Odum
would make the above statement. Considering
the many questions they raise above in under-
standing the procedures ofColerangle and Roy
(8, we would hope that they would also have
contactedtheoriginalauthors in thatstudy.
Ashby and Odum also raised tWO specific
questions about our studies (1,2). The first
question concerned examination of prostate
weight at 8 months ofage in one study with
prenatal exposure to estradiol and DES,
while bisphenol A-exposed animals were
examined at 6 months old of age. We had
conducted a preliminary study comparing
prostate weight in control CF-1 male mice
(five to nine males/group) at 6, 7, 8, 9.5, and
12.5 months of age, which resulted in the
following mean (± standard error) prostate
weights (in milligrams): 42.1 ± 2.5, 40.8 ±
2.7, 45.1 ± 3.8, 41.1 ± 2.8, and 61.3 ± 2.8,
respectively. These unpublished findings
showed that between 9 and 12 months of
age, male CF-1 mice experienced asignificant
increase in prostate weight, but between 6
and 9 months ofage, there was no significant
difference in prostate weight. We had initial-
ly waited until males were 8 months old to
examine effects of prenatal treatment with
estradiol and DES on the prostate due to
concern that effects might only be seen in
middle age (12). However, we have sought to
reduce the age at organ collection in these
studies to reduce costs. Relative to control
males, an increase in prostate weight was seen
at 6 months ofage in the bisphenol A study
and, more recently, was also found in 50-
day-old CF-1 male mice exposed prenatally
to lowdoses ofethinyl estradiol (13).
The second technical question concerned
the combination ofvehide control and unhan-
dled control animals into a single control
group in our studies. In all ofour experiments
we conduct an initial analysis just with these
two control groups. In every study that we
have conducted, this initial analysis has
revealed no statistical difference between the
two groups (the F value was 0.7 andp>O.4 for
this comparison in the bisphenol A study on
prostate weight); these animals were then com-
bined into one control group for comparison
to chemical treatment groups. Ashby and
Odum state, "that represents bad statistical
practice." However, an initial comparison of
multiple control groups is a common and
appropriate procedure, although from some
perspectives, there would be a decided advan-
tage in not taking this approach. Specifically,
the F ratio in analysis ofvariance is calculated
as the product ofvariation between groups
divided byvariation within groups. Thegreater
the number ofgroups with the same mean that
are placed into an analysis of variance, the
greater the reduction in the F ratio, and there-
fore thegreater theprobability offailingto find
statistical significance. The procedure recom-
mended by Ashby and Odum would thus
increase the likelihood of falsely concluding
that the test chemicalhad no effect.
The initial point made by Ashby and
Odum involves the discovery ofadverse effects
for chemicals by academic laboratories and that
the chemical industry is left tO confirm unrepli-
cated findings. It seems inappropriate to coin-
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plain that new results are published from
unreplicated experiments when, to be consid-
ered a valid replication, it requires that the
experiment must be conducted by different sci-
entists who are informed of new knowledge
from the initial publication. However, it is
interesting that Ashby and Odum acknowledge
that it is from academia that such new findings
emanate. In 1992, a consensus statement was
published by a diverse group of scientists who
attended the first meeting devoted to the issue
of endocrine disruption. There was consensus
that "the effects are most often manifested in
offspring, not in the exposed parent, and
although critical exposure occurs during embry-
onic development, obvious manifestations may
not occur until maturity" and that there is a
"lack of multi-generational exposure studies
thatsimulate ambient concentrations" ofpoten-
tial endocrine disruptors (14). Despite this con-
sensus statement in 1992, we know ofno prior
efforts by industry to address these concerns
about effects ofendocrine disruptors raised at
this meeting and in many subsequent publica-
tions. It appears that critical industry research
on endocrine disruptors may not have been
conducted because of the fear of finding new
adverse effects. A related problem is that the
credibility of industry-funded research will be
an issue as long as the research can be terminat-
ed if it appears that new adverse effects will
result in a loss of profitability. In contrast, in
academic research the rapid dissemination of
information is driven by the priority that is
given to first publication of new experimental
findings.
WadeV. Welshons
Department ofVeterinary Biomedical Sciences
University ofMissouri-Columbia
Columbia, Missouri
Susan C. Nagel
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